Table 1. The feature of included studies.
| First author | Public year | Study type | Location | Follow-up (mo) | Groups | Patients (n) | Mean age (a) | Gender radio (M/F) | Therapy |
| Larsen[15] | 2012 | RCT | Europe | 12 | Monotherapy | 133 | 75.5 | 59/74 | IVR (3+PRN) |
| Combination | 122 | 76.8 | 44/78 | PDT (SF1+PRN); IVR (3+PRN) | |||||
| Kaiser[17] | 2012 | RCT | America | 12 | Monotherapy | 112 | NR | NR | IVR (11) |
| PDT (SF) combination | 104 | NR | NR | PDT (SF1+PRN); IVR (3+PRN) | |||||
| PDT (RF) combination | 105 | NR | NR | PDT (RF1+PRN); IVR (3+PRN) | |||||
| Krebs[16] | 2013 | RCT | Austria | 12 | Monotherapy | 24 | 77.71 | NR | IVR (3+PRN) |
| Combination | 20 | 80.25 | NR | PDT (SF1+PRN); IVR (3+PRN) | |||||
| Vallance[13] | 2010 | RCT | UK | 12 | Montherapy | 9 | NR | NR | IVR (3+PRN) |
| Combination | 9 | NR | NR | PDT (SF1+PRN); IVR (3+PRN) | |||||
| Lim[14] | 2012 | RCT | Korea | 12 | Monotherapy | 13 | 66.7 | 8/5 | IVB (3+PRN) |
| Combination | 23 | 68.9 | 12/6 | PDT (SF1+PRN); IVB (3+PRN) | |||||
| Williams[12] | 2012 | RCT | American | 12 | Monotherapy | 27 | 79.1 | NR | IVB (1+PRN) |
| PDT (RF) combination | 29 | 79.3 | NR | PDT (RF1+PRN); IVB (1+PRN) | |||||
| Costagliola[19] | 2010 | RCT | Italy | 12 | Monotherapy | 45 | 65.3 | 20/25 | IVB (1+PRN) |
| PDT (RF) combination | 40 | 63.2 | 18/22 | PDT (RF1+PRN); IVB (1+PRN) | |||||
| Datseris[18] | 2015 | RCT | America | 12 | Monotherapy | 46 | 74 | 16/30 | IVB (1+PRN) |
| PDT (RF) combination | 49 | 73 | 13/36 | PDT (RF1+PRN); IVB (1+PRN) |
RCT: Randomized control trials; Monotherapy: Group which accept anti-VEGF treatment only; PDT (SF): PDT with standard fluence; PDT (RF): PDT with reduced fluence; BCVA: Best-corrected visual acuity; CRT: Central retinal thickness; IVR: Intravitreal ranibizumab; IVB: Intravitreal bevacizumab; PRN: As needed; NR: No record.